1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biotest AG

Biotest AG

BTTAY
Biotest AGUS flagOther OTC
24.21
USD
-0.02
- -
942.12MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
6.25
6.7
7.35
6.75
5.16
4.78
5.06
5.3
6.12
6.51
6.52
8.65
- -
8.18
Basic EPS, GAAP
0.47
0.42
0.24
-1.05
-0.58
-0.05
2.29
-0.06
-0.4
-0.81
-0.41
1.6
- -
-0.32
Free Cash Flow per Basic Share
-0.01
-0.67
-0.71
-0.71
-2.67
-0.91
-1.32
-0.86
-0.55
0.2
-0.88
-0.46
- -
0.19
Dividend per Share
0.08
0.08
0.1
0.1
0.02
0.03
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
Book Value per Share
3.07
3.14
3.22
2.43
1.78
1.61
3.48
3.25
2.8
2.03
1.91
3.66
- -
3.77
Tangible Book Value per Share
4.31
5.29
5.22
4.39
3.99
3.93
5.8
5.85
5.4
4.66
4.48
6.11
- -
6.35
Basic Weighted Avg Shares
70
75
79
79
79
79
79
79
79
79
79
79
- -
78
Sales/Revenue/Turnover
440
501
582
535
408
378
400
419
484
516
516
685
726
635
Operating Margin (%)
11.36
10.04
9.12
6.9
8.31
-8.81
0.62
-1.6
-0.52
-10.1
-1.65
18.89
11.8
1.72
Depreciation Expense
31
32
32
22
20
22
25
32
30
31
36
36
41
- -
Net Income, GAAP
33
32
19
-82
-46
-4
182
-5
-31
-63
-32
127
26
-24
Effective Tax Rate (%)
36.71
33.05
59.06
22.41
74.58
- -
- -
- -
- -
- -
- -
- -
43.44
323.93
Profit Margin (%)
7.59
6.39
3.3
-15.43
-11.23
-0.93
45.39
-1.12
-6.48
-12.3
-6.14
18.55
3.64
-3.86
Working Capital
202
438
550
461
321
198
370
408
451
416
489
371
649
629
LT Debt
71
226
326
336
330
287
329
402
461
490
565
382
592
- -
Total Equity
369
461
480
412
361
348
495
477
442
380
371
499
531
510
Return on Invested Capital (%)
6.46
5.7
2.86
3.63
1.18
- -
- -
- -
- -
- -
- -
- -
4.37
- -
Return on Capital (%)
13.33
8.65
4.38
-13.07
-8.02
- -
- -
- -
- -
- -
- -
- -
4.99
34.21
Return on Common Equity (%)
22.64
14.01
7.68
-37.1
-27.5
-2.91
89.98
-1.92
-13.28
-33.37
-20.58
57.64
8.75
-8.15

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
- -
6
- -
LT Borrowings
- -
538
- -
LT Finance Leases
- -
53
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
- -
1,836
1,638

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
704
810
789
Cash, Cash Equivalents & STI
38
120
60
Accounts Receivable, Net
132
158
155
Inventories
488
480
524
Total Current Liabilities
277
160
160
Payables & Accruals
- -
- -
- -
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.56%
3.42%
6.37%
Free Cash Flow
-73.22%
-190.69%
-189.2%
Net Income, GAAP
-602.04%
8.03%
-79.21%
Sales/Revenue/Turnover
3.23%
12.17%
6.08%
Total Cash Common Dividend
- -
- -
300%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
117
158
225
184
685
2024
215
157
151
204
726
2025
124
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.27
0.27
1.09
- -
1.6
2024
0.37
0.12
-0.12
- -
- -
2025
-0.27
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jorg Schuttrumpf
Full Time Employees
2,495
Sector
Healthcare
Industry
Biotechnology
Address
Landsteinerstrasse 5 Dreieich Germany 63303
IPO Date
Aug 8, 2022
Website
biotest.com
Similar Companies
Cambium Bio Limited (CMB.AX)
Servoteach Industries Limited (SERVOTEACH.BO)
NeonMind Biosciences Inc. (NMDBF)
Alpine Immune Sciences, Inc. (ALPN)
Prescient Therapeutics Limited (PSTTF)
Cuorips Inc. (4894.T)
Business
Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs derived from human blood plasma, focusing on clinical immunology, haematology and intensive care medicine; core products include immunoglobulins such as Intratect (50 g/l and 100 g/l), Yimmugo, Cytotect CP Biotest, Varitect CP, Pentaglobin, Hepatect CP and Zutectra; clotting factors such as Haemoctin SDH, Haemonine and Vihuma; and albumins such as Albiomin (5% and 20%) and Biseco, alongside coagulation factors like Cofact and development-stage products including Fibrinogen and Trimodulin. Founded in 1946 and headquartered in Dreieich near Frankfurt, Germany, the company operates production facilities in Dreieich with a capacity ramp-up to 3 million litres of plasma under the Biotest Next Level expansion, maintains over 40 plasma collection centres in Germany, Hungary and the Czech Republic, and markets products in more than 70 countries through subsidiaries in Austria, Switzerland and Hungary, as well as distribution partners including Grifols SA in select markets. Biotest, a majority-owned subsidiary of Grifols SA since its 2022 acquisition, reported 2024 revenue of EUR 726.2 million and employs approximately 2,500 people primarily in Germany; recent developments encompass FDA approval and planned 2025 US launch of Yimmugo via a seven-year exclusive distribution pact with Kedrion Biopharma projected to exceed USD 1 billion in revenue, marketing authorisation submissions for Fibrinogen in Europe and the US following successful phase III trials for acquired and congenital fibrinogen deficiency, divestiture of five sales entities to Grifols in 2023, intensified Grifols partnership for R&D and plasma supply, and opening of four new plasma centres in 2024.